Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Julian who wrote (801)	1/11/2000 12:30:00 AM
From: Julian	Read Replies (1) \| Respond to of 1321

QLTI is Janus Global Life Sciences Fund (JAGLX) largest single investment (9.8% as of 10/31/99). Here's what Thomas Malley, portfolio mgr for JAGLX, has to say about QLTI in the 1999 Annual Report: "Our exposure overseas remained modest despite the addition of a few unique and fundamentally sound foreign companies. One such addition was Canada's QLT PhotoTherapeutics, a company that develops and markets light-activated drugs for the treatment of cancer, autoimmune disorders, cardiovascular disease and ophthalmologic conditions. Visudyne, QLT's most promising product, stands virtually alone as a treatment for a common form of age-related macular degeneration, the leading cause of blindness in older adults. We believe Visudyne will enjoy smooth sailing through the FDA approval process, and we look for a strong commercial launch of the product during the first half of 2000."